Table of Contents Table of Contents
Previous Page  495 / 1631 Next Page
Information
Show Menu
Previous Page 495 / 1631 Next Page
Page Background

IMRT in lymphoma RT

IMRT has been thought to be less useful and still not regarded as a

standard option in hematological malignancies because:

o

Lower prescribed doses, generally well below tolerance dose of

normal tissues (QUANTEC)

o

Fear of late effects secondary to low-dose exposure of larger

volumes of healthy tissues